Bubendorf/Basel, October 7, 2014 – Bachem the leading peptide manufacturer, and GlyTech Inc. (Kyoto, Japan), the world-leading developer of glycosylated drugs, announced today that they have entered into a co-promotion agreement for GlyTech’s glycosylation technology. As part of the agreement, Bachem will leverage its sales and marketing resources to enhance GlyTech’s partnering efforts and GlyTech will promote Bachem as the partner of choice for manufacture of its glycopeptides and glycoproteins.